A health economic evaluation of the unnecessary ordering of coagulation studies and blood grouping prior to elective surgery.

Abstract

Unnecessary pathology tests add significant financial burden to health care expenditures while offering limited benefit to patients. Current guidelines do not support indiscriminate ordering of preoperative coagulation studies and ABO blood typing. We sought to estimate the incidence and financial cost of the indiscriminate ordering of these investigations in our institution. A single centre retrospective electronic chart review was performed in patients who underwent preoperative coagulation studies or ABO blood typing prior to elective surgery over a ten-month period. Using local evidence-based guidelines, only 9% of coagulation studies and 75% of ABO blood typing studies were indicated. The estimated cost of unnecessary tests in our cohort of 2688 patients was approximately AUD35,500. Interventions such as directed education and clinician feedback should be considered to combat the high incidence of indiscriminate ordering of preoperative coagulation studies and ABO blood typing.